Vaxxas, a biotechnology company commercializing a novel vaccination platform, announced MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) has exercised its option to utilize Vaxxas’ proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate.
